Syndax Pharmaceuticals (SNDX) Interest Expenses (2015 - 2026)
Syndax Pharmaceuticals (SNDX) posted quarterly Interest Expenses of $11.8 million for Q1 2026, up 47.5% year-over-year from $8.0 million in Q1 2025, and up 148.77% quarter-over-quarter from -$24.2 million in Q4 2025.
Syndax Pharmaceuticals (SNDX) Interest Expenses (2015 - 2026) Analysis & Trends
Syndax Pharmaceuticals' Interest Expenses history runs 12 years deep, the most recent figure standing at $11.8 million for Q1 2026.
- In Q1 2026, Interest Expenses rose 47.5% year-over-year to $11.8 million; the TTM figure through Mar 2026 stood at $3.9 million (down 69.87% YoY), while the FY2025 annual figure was $56.9 million, down 78.01% from the prior year.
- Interest Expenses for Q1 2026 stood at $11.8 million, up from -$24.2 million in the prior quarter.
- The five-year high for Interest Expenses was $11.8 million in Q1 2026, with the low at -$24.2 million in Q4 2025.
- The 5-year median for Interest Expenses is $756000.0 (2024), against an average of $1.3 million.
- Peak annual rise in Interest Expenses reached 35986.96% in 2025, while the deepest fall reached 596.08% in 2025.
- Syndax Pharmaceuticals' Interest Expenses stood at $41000.0 in 2022, then jumped by 53.66% to $63000.0 in 2023, then jumped by 7641.27% to $4.9 million in 2024, then slumped by 596.08% to -$24.2 million in 2025, then surged by 148.77% to $11.8 million in 2026.
- Business Quant data shows SNDX's Interest Expenses at $11.8 million in Q1 2026, -$24.2 million in Q4 2025, and $8.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 439.40 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 52.50 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.70 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 39.74 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 335,572.77 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 218.10 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 82.05 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 20.27 Mn |
| 10 | Syndax Pharmaceuticals | 1.77 Bn | 1.22 Bn | 60.67 Mn | 12.10 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 12.10 Mn |
| Jun 30, 2026 | 12.10 Mn |
| Mar 31, 2026 | 11.80 Mn |
| Mar 31, 2026 | 11.80 Mn |
| Dec 31, 2025 | -24.19 Mn |
| Dec 31, 2025 | -24.19 Mn |
| Sep 30, 2025 | 8.30 Mn |
| Sep 30, 2025 | 8.30 Mn |
| Jun 30, 2025 | 6.15 Mn |
| Jun 30, 2025 | 6.15 Mn |
| Mar 31, 2025 | 8.00 Mn |
| Mar 31, 2025 | 8.00 Mn |
| Dec 31, 2024 | 4.88 Mn |
| Dec 31, 2024 | 4.88 Mn |
| Sep 30, 2024 | 23,000.00 |
| Sep 30, 2024 | 23,000.00 |
| Jun 30, 2024 | 817,000.00 |
| Jun 30, 2024 | 817,000.00 |
| Mar 31, 2024 | 756,000.00 |
| Mar 31, 2024 | 756,000.00 |